Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.26.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2026
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended

​

Nine-Month Periods Ended

​

​

September 30, 

​

September 30, 

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi®

​

$

9,002

​

$

4,883

​

$

23,329

​

$

9,748

Qbrexza®

​

​

5,590

​

​

7,361

​

​

15,732

​

​

19,470

Accutane®

​

 

3,023

​

 

2,769

​

 

9,694

​

 

9,818

Foam franchise products (Amzeeq® & Zilxi®)

​

​

942

​

​

1,311

​

​

2,933

​

​

3,973

Other / legacy

​

​

368

​

​

701

​

​

997

​

​

2,164

Total product revenues

​

$

18,925

​

$

17,025

​

$

52,685

​

$

45,173

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended 

​

Nine-Month Periods Ended

​

​

September 30, 

​

September 30, 

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cutia supply agreement

​

$

—

​

$

606

​

$

635

​

$

606

Royalties on sales of Amzeeq by Cutia

​

​

42

​

​

—

​

​

118

​

​

—

Total other revenue

​

$

42

​

$

606

​

$

753

​

$

606